Viatronix's V3D-Colon software used in another clinical study relating to colorectal cancer screening

NewsGuard 100/100 Score

Viatronix Incorporated announced today that its dedicated CT Colonography (CTC) software—V3D-Colon was exclusively used in another important clinical study relating to colorectal cancer screening. The latest CTC study, "Assessment of volumetric growth rates of small colorectal polyps with CT colonography: a longitudinal study of natural history" (Lancet Oncology, online June 7, 2013), tracked polyp growth in 243 patients over an eight year period.

For the first time there is direct evidence and statistical proof that colorectal polyp-volume growth over time delivers true clinical value for identifying advanced adenomas. The advanced adenoma polyp is the primary target in colorectal cancer screening. When an advanced adenoma polyp is identified and removed the likelihood of colorectal cancer developing is significantly reduced.

"Viatronix is extremely proud to have been an integral part of such an important trial," said Zaffar Hayat, President and CEO of Viatronix Incorporated. He went on to say, "The Viatronix platform has been the software of choice in several landmark clinical trials over the past ten years. V3D-Colon's user friendly interface, diagnostic tools and short read times backed by strong clinical validation make it the system of choice for leading experts."

This study once again proves CTC is effective for colon cancer screening.

Screening CTC is currently reimbursed by many insurance carriers and coverage is mandated in approximately 30 States. Presently there is legislation in Congress for CMS/Medicare to cover the cost for this invaluable colorectal cancer screening exam.


Viatronix Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study identifies key protein biomarkers for early detection of pancreatic cancer